AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Sopran - Omeprazole Treatment Versus Surgery
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-11-22
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 219
- Registration Number
- NCT00256737
- Locations
- 🇸🇪
Research Site, Örebro, Sweden
The IRESSA Novel Head and Neck Chemotherapy Evaluation Study
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 64
- Registration Number
- NCT00255476
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Seroquel® Combined With Cognitive Remediation Therapy to Conventional Treatment in Patients With Schizophrenia
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 85
- Registration Number
- NCT00255515
- Locations
- 🇸🇪
Research Site, Vasteras, Sweden
Dose Ranging, Safety and Tolerability of TOPROL-XL® Extended-Release Tablets in Hypertensive Pediatric Subjects
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2007-03-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 144
- Registration Number
- NCT00255528
- Locations
- 🇩🇴
Research Site, Santo Domingo, Dominican Republic
A Phase I Study of ZD1839 and Palliative Thoracic Radiotherapy in Patients With Non-small-cell Lung Cancer
Phase 1
Completed
- Conditions
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT00255489
- Locations
- 🇬🇧
Research Site, Leeds, United Kingdom
307B - Safety, Tolerability and Pharmacokinetics Study of TOPROL-XL® in Hypertensive Pediatric Subjects
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT00255502
- Locations
- 🇩🇴
Research Site, Santa Domingo, Dominican Republic
Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 185
- Registration Number
- NCT00255463
- Locations
- 🇬🇧
Research Site, Poole, United Kingdom
GALLANT 4 Tesaglitazar vs. Glibenclamide
Phase 3
Terminated
- Conditions
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2008-03-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 580
- Registration Number
- NCT00255541
- Locations
- 🇹🇭
Research Site, Bangkok, Thailand
G-PLUS (GALLANT, GALLEX and ARMOR - Post Treatment Follow-up Study)
Terminated
- Conditions
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2008-03-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4500
- Registration Number
- NCT00255645
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Safety & Efficacy of Symbicort® Turbuhaler® (1, 2, and 4 x 160/4.5 µg Twice Daily) in Japanese Patients With Asthma
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-11-18
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT00255255
- Locations
- 🇯🇵
Research Site, Kochi, Japan
© Copyright 2024. All Rights Reserved by MedPath